The 340B Drug Pricing Program continues to undergo significant transformation, which will only accelerate in the coming months. This webinar led by Partner of Advisory Services, Clay Willis, provided a comprehensive, expert-led overview of the current 340B environment, including the latest developments in around the rebate model, in-house policies, and contract pharmacy policies.

A key component of the discussion centered the growing importance of not only obtaining the 340B claims data, but the access and use of the 340B claims data in a manufacturers net-revenue platform to better solve the 340B duplicate discounts problem more efficiently and effectively. Attendees learned about the 340B claim movement, the operational challenges that exist today, and how manufacturers are now realizing those and starting to focus on ways to control the 340B claims.

This session equipped those wanting to learn about what is changing around the 340B landscape or optimizing 340B operations for the future with timely insights, actionable strategies, and a forward-looking perspective on where the program is heading next.

• Monday, July 27th
• 1:00 PM EST